Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Sa | Key deals this week: Amcor, ONEOK, Grifols, N-able and more | 4 | Seeking Alpha | ||
Do | Grifols believes Brookfield's non-binding offer greatly undervalues fundamental prospects and long-term potential | 35 | thecorner.eu | ||
Mi | Plasma specialist Grifols shrugs off private equity firm Brookfield's potential €6.5B takeover offer | 20 | FiercePharma | ||
Mi | Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% | 10 | Zacks | ||
Mi | Grifols rejects Brookfield's 'undervalued' $6.8bn bid | 19 | Private Equity Wire | ||
Mi | Grifols Says It Would Not Recommend Shareholders Accept Brookfield's Bid Offer | 15 | Reuters | ||
GRIFOLS SA ADR 1/2/EO Aktie jetzt für 0€ handeln | |||||
Di | Grifols slips as board rebuffs Brookfield's $6.8B offer (update) | 9 | Seeking Alpha | ||
Di | Grifols Board Issues Unfavorable Opinion on Brookfield Offer | 9 | BNN Bloomberg | ||
Di | Grifols: Brookfields potential $6.8 billion offer undervalues the firm | 28 | Reuters | ||
Di | Brookfield Weighs €6.45 Billion Bid for Grifols; Shares Drop | 10 | BNN Bloomberg | ||
Di | Grifols SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
Di | Grifols Transaction Committee May Not Support Brookfield's Bid Offer | 13 | Reuters | ||
Di | Brookfield considering offer for Grifols valuing it at 6.45 billion euros | 15 | Reuters | ||
Di | Brookfield Confirms Requesting Information On Grifols To Finish Due Diligence | 11 | Reuters | ||
Di | Grifols linked to €7bn takeover offer from Brookfield | 25 | pharmaphorum | ||
Di | Mason Capital Demands Paul Herendeen Be Added To Grifols Board | 10 | Reuters | ||
Di | Mason Capital Management LLC: Mason Capital Reiterates Corporate Governance Shortcomings and Mismanagement of Grifols Under Current Board of Directors | 281 | Business Wire | Believes Substantially Greater Value Than Any Brookfield Bid Can Be Realized by Ousting Conflicted Directors and Restoring Majority Control of Independent Shareholders Demands Rightful Addition... ► Artikel lesen | |
Mo | MÄRKTE EUROPA/Knapp behauptet - Grifols mit angeblicher Offerte unter Druck | 1.330 | Dow Jones News | DJ MÄRKTE EUROPA/Knapp behauptet - Grifols mit angeblicher Offerte unter Druck
DOW JONES--Der europäische Aktienmarkt ist mit kleinen Abgaben in die neue Woche gestartet. Das negative Umfeld an... ► Artikel lesen | |
Mo | Brookfield weighs $7.4bn bid for Spain's Grifols | 15 | Private Equity Wire | ||
Mo | MIDDAY BRIEFING - Unternehmen und Märkte: COMMERZBANK, DELIVERY HERO, KAUFLAND, STO, ENEL, GRIFOLS, RBI, SHEIN GROUP, SPIRIT AIRLINES, TELEFONICA | 1.423 | Dow Jones News | DJ MIDDAY BRIEFING - Unternehmen und Märkte
Der Markt-Überblick am Mittag, zusammengestellt von Dow Jones Newswires:
+++++ AKTIEN- UND ANLEIHEMÄRKTE (13:09 Uhr) +++++
INDEX ... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MERCK KGAA | 141,75 | +2,49 % | JPMORGAN stuft MERCK KGAA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Merck KGaA mit einem Kursziel von 190 Euro auf "Overweight" belassen. Das für 2025 gesteckte Ziel eines operativen Gewinnwachstums... ► Artikel lesen | |
GSK | 16,295 | +2,65 % | GSK Plc Announces Regulatory Expansion For Arexvy In Japan To Include Adults Aged 50-59 | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - GSK plc (GSK, GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has approved a regulatory application to extend the indication of Arexvy... ► Artikel lesen | |
VERTEX PHARMACEUTICALS | 434,35 | +0,32 % | Goldman Sachs: Vertex Pharmaceuticals Incorporated (VRTX) Is A Top Growth Investor Stock | ||
BAUSCH HEALTH | 7,869 | +2,90 % | Bausch Health Companies Inc.: Bausch Health and Salix to Present at the American Association for the Study of Liver Disease the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis | Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)... ► Artikel lesen | |
ALNYLAM PHARMACEUTICALS | 235,60 | +0,21 % | Alnylam Presents New Phase 1 Results For Next-Gen RNAi Therapy Nucresiran In ATTR Amyloidosis | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) has shared new findings from its Phase 1 study of nucresiran (previously known as ALN-TTRsc04), a next-generation RNAi therapy being... ► Artikel lesen | |
NEKTAR THERAPEUTICS | 0,951 | -5,33 % | Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence | - NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions -
SAN FRANCISCO, Nov. 18,... ► Artikel lesen | |
APONTIS PHARMA | 9,640 | -1,43 % | Apontis Pharma: "Wir haben unsere Hausaufgaben gemacht" | Zentiva bietet den Aktionären der Apontis Pharma im Rahmen eines öffentlichen Erwerbsangebots einen Betrag von 10,00 Euro je Aktie. Vorstand und Aufsichtsrat von Apontis Pharma halten den Angebotspreis... ► Artikel lesen | |
MEDPACE | 324,10 | 0,00 % | Medpace Holdings, Inc. Reports Third Quarter 2024 Results | CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced financial results for the third quarter ended September 30, 2024.
Third Quarter 2024 Financial Results
Revenue... ► Artikel lesen | |
CANTOURAGE GROUP | 4,500 | +3,21 % | EQS-News: Cantourage Group SE: Neuer Umsatzrekord: Cantourage Group SE erzielt EUR 5,5 Mio. Umsatz im Oktober 2024 und bestätigt Wachstumsziele für das Gesamtjahr | EQS-News: Cantourage Group SE
/ Schlagwort(e): Umsatzentwicklung/Monatszahlen
Neuer Umsatzrekord: Cantourage Group SE erzielt EUR 5,5 Mio. Umsatz im Oktober 2024 und bestätigt... ► Artikel lesen | |
TITAN PHARMACEUTICALS | 0,001 | 0,00 % | Titan Pharmaceuticals, Inc.: Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd. | NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan") today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the... ► Artikel lesen | |
SCYNEXIS | 1,123 | -3,36 % | SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to... ► Artikel lesen | |
INVENTIVA | 2,395 | -2,24 % | INVENTIVA: Inventiva reports 2024 Third Quarter Financial Information | Cash and cash equivalents at €13.9 million, as of September 30, 2024.Revenues of €1.3 million for the first nine months of 2024.On July 18, 2024, Inventiva issued royalty certificates for an amount... ► Artikel lesen | |
CHAMPIONS ONCOLOGY | 3,960 | -0,50 % | Champions Oncology, Inc.: Champions Oncology Announces Agreement with Weill Cornell Medicine | HACKENSACK, NJ / ACCESSWIRE / October 16, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, is pleased to announce a licensing agreement... ► Artikel lesen | |
GABATHER | 0,039 | +35,92 % | Nasdaq Stockholm AB: New equity right for trading, Gabather TO 6 | At the request of Gabather AB, equity rights TO 6 will be traded on First North
Growth Market as from 5 September 2024.
Security name: Gabather TO 6
-----------------------------
Short name: GABA... ► Artikel lesen | |
BAYER | 19,802 | +1,46 % | DAX-Check LIVE: Adesso, Allianz, Bayer, Conti, GFT, Porsche SE, Rheinmetall, Siemens Energy, Thyssen | Vor dem Wochenende verzeichnete der DAX leichte Verluste in Höhe von knapp 0,3 Prozent. Auf Wochensicht bewegte sich der deutsche Leitindex jedoch abermals kaum vom Fleck. Worauf es jetzt für den DAX... ► Artikel lesen |